← All trials
NCT05027802
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2021
- Primary completion
- Nov 11, 2024
- Completion date
- Nov 11, 2024
- First posted
- Aug 30, 2021
- Last posted
- Sep 14, 2021
- Enrollment
- 61
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.